Cryptococcosis in apparently immune-competent patients: taxonomy, epidemiology, pathophysiology and treatment

References

• Hagen F, Khayhan K, Theelen B, et al. Recognition of seven species in the Cryptococcus gattii/Cryptococcus neoformans species complex. Fungal Genet Biol. 2015 May;78:16–48.10.1016/j.fgb.2015.02.009
   PubMed Web of Science ®Google Scholar
• Park BJ, Rajasingham R, Smith R, et al. Update on the global burden of cryptococcosis. Oral Abstract presented at: ICCC;Amsterdam; 2014; .
   Google Scholar
• Jarvis JN, Meintjes G, Williams A, et al. Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. BMC Infect Dis. 2010;10(1):67.10.1186/1471-2334-10-67
   PubMed Web of Science ®Google Scholar
• Britz E, Mollendorf C, von Gottberg A, et al. The epidemiology of bacterial and fungal meningitis among adults in Gauteng Province, 2009–2013 [Internet]. Oral Presentation presented at: FIDSSA; 2015 Nov; South Africa. Available from: http://www.mm3admin.co.za/documents/docmanager/47f686f5-acdf-4462-8366-64afd5633d81/00090269.pdf.
   Google Scholar
• National Institute for Communicable Diseases. Surveillance report Cryptococcus species. GERMS-SA Annual Report 2015. NICD; 2015.
   Google Scholar
• Pappas PG, Perfect JR, Cloud GA, et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis. 2001 Sep;33(5):690–9.10.1086/cid.2001.33.issue-5
   PubMed Web of Science ®Google Scholar
• Bratton EW, El Husseini N, Chastain CA, et al. Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative/non-transplant. In: Scheurer M, editor. PLoS ONE. 2012 Aug 24;7(8):e43582.10.1371/journal.pone.0043582
   PubMed Web of Science ®Google Scholar
• Lui G, Lee N, Ip M, et al. Cryptococcosis in apparently immunocompetent patients. QJM. 2006 Mar;99(3):143–51.10.1093/qjmed/hcl014
   PubMed Web of Science ®Google Scholar
• Mitchell DH, Sorrell TC, Allworth AM, et al. Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome. Clin Infect Dis. 1995 Mar;20(3):611–6.10.1093/clinids/20.3.611
   PubMed Web of Science ®Google Scholar
• Meiring ST, Quan VC, Cohen C, et al. A comparison of cases of paediatric-onset and adult-onset cryptococcosis detected through population-based surveillance, 2005–2007. AIDS. 2012 Nov;26(18):2307–14.10.1097/QAD.0b013e3283570567
   PubMed Web of Science ®Google Scholar
• Goldman DL, Khine H, Abadi J, et al. Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics. 2001 May;107(5):e66.10.1542/peds.107.5.e66
   PubMedGoogle Scholar
• Deshaw M, Pirofski LA. Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV− individuals. Clin Exp Immunol. 1995 Mar;99(3):425–32.
   PubMed Web of Science ®Google Scholar
• Fleuridor R, Lyles RH, Pirofski L. Quantitative and qualitative differences in the serum antibody profiles of human immunodeficiency virus–infected persons with and without Cryptococcus neoformans meningitis. J Infect Dis. 1999 Nov;180(5):1526–35.10.1086/jid.1999.180.issue-5
   PubMed Web of Science ®Google Scholar
• Abadi J, Pirofski L. Antibodies reactive with the cryptococcal capsular polysaccharide glucuronoxylomannan are present in sera from children with and without human immunodeficiency virus infection. J Infect Dis. 1999 Sep;180(3):915–9.10.1086/jid.1999.180.issue-3
   PubMed Web of Science ®Google Scholar
• Garcia-Hermoso D, Janbon G, Dromer F. Epidemiological evidence for dormant Cryptococcus neoformans infection. J Clin Microbiol. 1999 Oct;37(10):3204–9.
   PubMed Web of Science ®Google Scholar
• Ma H, May R. Virulence in Cryptococcus species. In: Advances in applied microbiology. Burlington, VT: Academic Press; 2009. p. 131–90.
   Google Scholar
• May RC, Stone NRH, Wiesner DL, et al. Cryptococcus: from environmental saprophyte to global pathogen. Nat Rev Microbiol. 2015 Dec 21;14(2):106–17.10.1038/nrmicro.2015.6
   PubMed Web of Science ®Google Scholar
• Rohatgi S, Pirofski L. Host immunity to Cryptococcus neoformans. Future Microbiol. 2015 Apr;10(4):565–81.10.2217/fmb.14.132
   PubMed Web of Science ®Google Scholar
• Coelho C, Bocca AL, Casadevall A. The intracellular life of Cryptococcus neoformans. Annu Rev Pathol Mech Dis. 2014 Jan 24;9(1):219–38.10.1146/annurev-pathol-012513-104653
   PubMed Web of Science ®Google Scholar
• Steenbergen JN, Shuman HA, Casadevall A. Cryptococcus neoformans interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages. Proc Natl Acad Sci USA. 2001 Dec 18;98(26):15245–50.10.1073/pnas.261418798
   PubMed Web of Science ®Google Scholar
• Tucker SC, Casadevall A. Replication of Cryptococcus neoformans in macrophages is accompanied by phagosomal permeabilization and accumulation of vesicles containing polysaccharide in the cytoplasm. Proc Natl Acad Sci USA. 2002 Mar 5;99(5):3165–70.10.1073/pnas.052702799
   PubMed Web of Science ®Google Scholar
• Casadevall A, Steenbergen JN, Nosanchuk JD. ‘Ready made’ virulence and ‘dual use’ virulence factors in pathogenic environmental fungi —the Cryptococcus neoformans paradigm. Curr Opin Microbiol. 2003 Aug;6(4): 332–7.
   PubMed Web of Science ®Google Scholar
• Kapoor A, Flechner SM, O’Malley K, et al. Cryptococcal meningitis in renal transplant patients associated with environmental exposure. Transpl Infect Dis. 1999 Sep;1(3):213–7.10.1034/j.1399-3062.1999.010309.x
   PubMedGoogle Scholar
• Nosanchuk JD, Shoham S, Fries BC, et al. Evidence of zoonotic transmission of Cryptococcus neoformans from a pet cockatoo to an immunocompromised patient. Ann Intern Med. 2000 Feb 1;132(3):205–8.10.7326/0003-4819-132-3-200002010-00006
   PubMed Web of Science ®Google Scholar
• Desmet P, kayembe K, Vroey C. The value of cryptococcal serum antigen screening among HIV-positive/AIDS patients in Kinshasa, Zaire. AIDS. 1989;3(2):77–8.
   PubMed Web of Science ®Google Scholar
• French N, Gray K, Watera C, et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 2002 May 3;16(7):1031–8.10.1097/00002030-200205030-00009
   PubMed Web of Science ®Google Scholar
• Jarvis JN, Lawn SD, Vogt M, et al. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis. 2009 Apr;48(7):856–62.10.1086/598925
   PubMed Web of Science ®Google Scholar
• Lara-Peredo O, Cuevas LE, French N, et al. Cryptococcal infection in an HIV-positive Ugandan population. J Infect. 2000 Sep;41(2):195.10.1053/jinf.2000.0697
   PubMed Web of Science ®Google Scholar
• Liechty CA, Solberg P, Were W, et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health TM IH. 2007 Aug;12(8):929–35.10.1111/tmi.2007.12.issue-8
   PubMed Web of Science ®Google Scholar
• Longley N, Jarvis JN, Meintjes G, et al. Cryptococcal antigen screening in patients initiating ART in South Africa: a prospective cohort study. Clin Infect Dis. 2016 Mar 1;62(5):581–7.
   PubMed Web of Science ®Google Scholar
• Meyer A-CL, Kendi CK, Penner JA, et al. The impact of routine cryptococcal antigen screening on survival among HIV-infected individuals with advanced immunosuppression in Kenya. Trop Med Int Health. 2013 Apr;18(4):495–503.10.1111/tmi.12067
   PubMed Web of Science ®Google Scholar
• Osazuwa F, Dirisu JO, Okuonghae PE, et al. Screening for cryptococcal antigenemia in anti-retroviral naïve AIDS patients in Benin City, Nigeria. Oman Med J. 2012 May 16;27(3):228–31.10.5001/omj.2012.51
   PubMedGoogle Scholar
• Oyella J, Meya D, Bajunirwe F, et al. Prevalence and factors associated with cryptococcal antigenemia among severely immunosuppressed HIV-infected adults in Uganda: a cross-sectional study. J Int AIDS Soc. 2012;15(1):15.10.1186/1758-2652-15-15
   PubMed Web of Science ®Google Scholar
• Rugemalila J, Maro VP, Kapanda G, et al. Cryptococcal antigen prevalence in HIV-infected Tanzanians: a cross-sectional study and evaluation of a point-of-care lateral flow assay. Trop Med Int Health. 2013 Sep;18(9):1075–9.10.1111/tmi.12157
   PubMed Web of Science ®Google Scholar
• Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010 Feb;50(3):291–322.10.1086/649509
   PubMed Web of Science ®Google Scholar
• Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med. 1979 Jul 19;301(3):126–31.10.1056/NEJM197907193010303
   PubMed Web of Science ®Google Scholar
• Dismukes WE, Cloud G, Gallis HA, et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med. 1987 Aug 6;317(6):334–41.10.1056/NEJM198708063170602
   PubMed Web of Science ®Google Scholar